The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 40 | — | 20.1x | Near average | |
Growth | 14 | -79.5% | 5.6% | Below average | |
Quality | 40 | -49.6% | 7.6% | Near average | |
Safety | 75 | 0.3x | 0.4x | Above average | |
Capital Return | 20 | 0.00% | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Dianthus Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Dianthus Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
DNTH stock shows remarkable stability in the average price target at 111.91 dollars over the past thirty days, with a consensus from 5 analysts. Despite the stability of expectations, a wide gap (Dispersion) stands out between the low of 55 dollars and the high of 145 dollars, reflecting a state of uncertainty regarding the drug development timeline or anticipated clinical results, even though the current price (86.48) remains below the average target.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.